Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
epratuzumab · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| epratuzumab | DRUG | - |
* Diagnosis of relapsed or refractory low-grade, CD20+, B-cell NHL \* Received and failed at least 1 prior regimen of chemotherapy \* Rituximab-naive or received prior rituximab in their last treatment (single agent or in combination with chemotherapy) and demonstrated a time to progression of at le...
Epratuzumab is an investigational drug being studied for the treatment of Non-Hodgkin's Lymphoma, specifically low-grade forms of the disease. It is currently in Phase 2 clinical development and has not been approved by the FDA. The drug is being developed by Amgen Inc. (NASDAQ: AMGN).
Epratuzumab is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN. The drug is currently in Phase 2 clinical trials for Non-Hodgkin's Lymphoma and remains investigational, meaning it has not yet received regulatory approval.
Epratuzumab is in Phase 2 clinical development for Non-Hodgkin's Lymphoma. It is an investigational drug, meaning it has not been approved by the FDA for any use. One Phase 2 trial has been completed, and the drug is not currently in any active clinical trials.
Epratuzumab has been studied in one completed Phase 2 clinical trial registered as NCT00044902, titled 'Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade).' This trial enrolled adults aged 18 years and older with Non-Hodgkin's Lymphoma. The trial was uncontrolled and did not use randomization or blinding.
No, epratuzumab is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Non-Hodgkin's Lymphoma. While one Phase 2 trial has been completed, the drug has not yet demonstrated sufficient evidence to receive regulatory approval for any indication.